{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T06:43:26.399188+00:00","company":{"ticker":"ZIVO","cik":1101026,"company_name":"Zivo Bioscience, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"debt_financing","fact_key":"1b3d57d07f330ab826b6d9ec12727098bcad7ccd","cik":1101026,"ticker":"ZIVO","company_name":"Zivo Bioscience, Inc.","filed_at":"2025-07-14T23:59:59+00:00","payload":{"counterparty":"an accredited investor","effective_date":"2025-07-08","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"10% interest per annum","item_codes_triggered":["2.03"],"maturity_text":"two years after the date of issuance","principal_text":"$250,000"},"claim":"Zivo Bioscience, Inc. incurred convertible notes of $250,000 with an accredited investor at 10% interest per annum maturing two years after the date of issuance.","evidence_excerpt":"On July 8, 2025, Zivo Bioscience, Inc. (the“Company”) issued a Bridge Promissory Note in the principal amount of $250,000 and accompanying warrant to purchase 1,793 shares","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001654954-25-008035","anchor_url":"https://secwatch.observer/filing/0001654954-25-008035#claim-1b3d57d07f330ab826b6d9ec12727098bcad7ccd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425008035/0001654954-25-008035-index.htm"},{"fact_type":"executive_change","fact_key":"173a474935","cik":1101026,"ticker":"ZIVO","company_name":"Zivo Bioscience, Inc.","filed_at":"2024-07-17T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Laith Yaldoo was appointed as Director at Zivo Bioscience, Inc..","evidence_excerpt":"On July 11, 2024, the Board of Directors of ZIVO Bioscience Inc., (the “Company”) increased its size from four (4) to five (5) members and appointed Laith Yaldoo to fill the vacancy.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001654954-24-009069","anchor_url":"https://secwatch.observer/filing/0001654954-24-009069#claim-173a474935","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424009069/0001654954-24-009069-index.htm"}]}